Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

Related Keywords

Belgium ,Brussels ,Bruxelles Capitale ,Enfermedades Raras ,Jonathan Schwartz ,Kinnari Patel ,Medioambientalesy Tecnol ,Bitha Narayanan ,Investigaciones Energ ,European Society Of Gene Cell Therapy ,Rocket Pharmaceuticals Inc ,Nasdaq ,Rocket Pharmaceuticals ,Annual Congress ,European Society ,Cell Therapy ,Pyruvate Kinase Deficiency ,Fanconi Anemia ,Danon Disease ,Chief Operating Officer ,Rocket Pharma ,Invited Talk ,Invited Talks ,Global Phase ,Lentiviral Mediated Gene Therapy ,Severe Pyruvate Kinase Deficiency ,Integrative Vectors ,Embracing Collaboration ,Drive Gene Therapy Forward ,Gene Therapy ,Clinical Implications ,Hematopoietic Diseases Gene Therapy ,Human Experience ,Muscular Diseases ,Chief Gene Therapy Officer ,Preclinical Efficacy ,Arrhythmogenic Cardiomyopathy ,Senior Director ,Kinase Deficiency ,Centro De Investigaciones Energ ,Centro De Investigaci ,Red De Enfermedades Raras ,Instituto De Investigaci ,Sanitaria De La Fundaci ,Leukocyte Adhesion Deficiency I ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Markets ,